Icon’s PMG Research partners with IL-based medical group

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/cofotoisme)
(Image: Getty/cofotoisme)
Icon has announced a clinical research partnership with DuPage Medical Group, a Chicago, IL-based network with more than 700 physicians across more than 100 locations.

Icon and DuPage Medical Group of Chicago, IL have finalized a Master Agreement formalizing the clinical research partnership.

Effective this month, PMG Research – part of Icon Site and Patient Recruitment​ – will assume the research infrastructure at the DuPage Medical Group. PMG currently operates 53 clinics in 14 cities in North America.

According to the company, the PRG Research network expansion increases Icon’s access to patients and investigator sites. In turn, the deal will see a clinical research as a care option at DuPage Medical Group.

"Recognising one of the industry’s biggest challenges is patient recruitment, Icon is responding by increasing investigator site and patient access to clinical research," ​an Icon spokesperson told Outsourcing-Pharma.

PMG works to operationalize clinical research within health care systems by managing research infrastructure and processes, which in turn enables healthcare professionals to focus patient treatment, they explained. 

The spokesperson added: "In this particular case, DuPage Medical Group is providing Icon with access to physicians and patients in more than 100 locations thereby providing a broader spectrum of research study opportunities for its physician and patient population, connecting interested individuals with participating research physicians and providing clinical research as a care option to its patients and in a more streamlined manner."

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more